ReviewFrontiers in pharmacology2026
The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are revolutionizing the management of metabolic and liver diseases, demonstrating effectiveness in controlling blood sugar levels and promoting liver repair. Research suggests that they have protective effects on the liver, demonstrating the potential for fibrosis regression and improved survival rates in patients with advanced liver disease. To synthesize recent advancements in the hepatoprotective effects of GLP-1RAs and their underlying mechanisms, we aimed to provide a comprehensive framework for the development of targeted therapeutics. Our data sources included PubMed and Web of Science, with search terms such as "GLP-1RAs," "liver," "MASLD," "HCC," "inflammatory," "microbiota," "metabolism," and their combinations. We selected reviews, clinical trials, and basic research articles from the past 5 years. GLP-1RAs provide a comprehensive defense against liver damage by exhibiting anti-inflammatory effects and promoting metabolic changes. They significantly modify the immune microenvironment, lower pro-inflammatory cytokines, and prevent the activation of hepatic stellate cells (HSCs), thereby helping to reduce fibrogenesis. This immune-metabolic modulation enhances their effectiveness in treating chronic liver conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis, and hepatocellular carcinoma (HCC). The combined clinical benefits and mechanistic insights position GLP-1RAs as leaders in addressing glycemic dysregulation and liver diseases, suggesting a transformative approach to the association between metabolic disorders and liver conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.